Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1 peptide-pulsed dendritic cell vaccine (Shinshu University)
- Development stage
- Unknown
- Lead developer
- Center for Advanced Cell Therapy, Shinshu University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
WT1 peptide-pulsed dendritic cell vaccine is an autologous cellular immunotherapy designed to treat cancers overexpressing the Wilms' tumor 1 (WT1) protein. The vaccine is produced by harvesting a patient's peripheral blood mononuclear cells, differentiating them into dendritic cells (DCs), and loading them with WT1-derived peptides. These pulsed DCs are then injected back into the patient, where they present WT1 antigens to the immune system, specifically activating cytotoxic T lymphocytes (CTLs) to recognize and destroy WT1-positive tumor cells. In clinical studies like the PANC-DC/S1 trial in Japan, this vaccine is being evaluated as an adjuvant treatment following curative resection for pancreatic cancer, often in combination with chemotherapy such as S-1, to prevent recurrence and improve survival outcomes.
- Other names
- WT1-pulsed dendritic cell vaccineWT-1-pulsed dendritic cell vaccineWT 1-pulsed dendritic cell vaccineWT1-DC vaccineWT-1-DC vaccineWT 1-DC vaccineWT1-pulsed DC vaccineWT-1-pulsed DC vaccineWT 1-pulsed DC vaccine
02
Targets
WT1-TCR (WT1-specific T-cell receptor)WT1-HLA-II (Wilms tumor protein 1-derived peptide-human leukocyte antigen class II complex)Wilms' tumor 1-derived peptide-human leukocyte antigen class I complex
Beyond the preview
Go deeper on WT1 peptide-pulsed dendritic cell vaccine (Shinshu University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1 peptide-pulsed dendritic cell vaccine (Shinshu University).